Table 3 CRS and HIPEC
Author, year | Pat. [n] | Cytostatic agents (HIPEC) | Median OS [mths] | Median PFS [mths] | OS [%] | Survival CC-0/1 [%] |
|---|---|---|---|---|---|---|
Pilati, 2003 [66] | 34 | MMC/DDP | 18 | - | 31 (2-y) | - |
Glehen, 2004 [67] | 53 | MMC | 13 | - | 32 (2-y) | 54 (2-y) |
Glehen, 2004 [63] | 506 | MMC/LOHP | 19 | - | 39 (3-y) | 47 (3-y) |
Shen, 2004 [68] | 77 | MMC | 16 | - | 25 (3-y) | 44 (3-y) |
105 | MMC | 22 | 12.6 | 28 (3-y) | 45 (5-y) | |
Quenet, ASCO 08 [69] | 37 | LOHP/IRI | 37 | 13 | - | 58 (3-y) |
Elias, 2009 [46] | 48 | LOHP | 63 | - | - | 51 (5-y) |
Hompes, 2012 [65] | 48 | LOHP | - | 19.8 | - | 89 (2y) |